Board.
Total 9 .
SCAI Therapeutics Secures 13 Billion KRW in Funding, Accelerating 'Two-Track' Strategy in Novel Drugs and Beauty
2026-07-13
SCAI Therapeutics Receives IND Approval for Phase 2 Clinical Trial of ‘VEGFR Eye Drops’ for Age-Related Macular Degeneration in Korea
2026-05-20
SCAI Therapeutics Successfully Completes Phase 1 Clinical Trial for Wet AMD Eye Drop Candidate ‘SCAI-005’
2026-01-30
SCAI Therapeutics Initiates Development of an ‘Inlyta-Based’ Ophthalmic Drop for the Treatment of Macular Degeneration
2025-04-02
SCAI Therapeutics Confirms Efficacy and Safety of Dry Eye Drops in Phase 2 Clinical Trials
2024-01-24
SCAI Therapeutics Receives IND Approval for Domestic Phase 2 Clinical Trial of ‘Improved CsA1’ for Dry Eye Disease
2022-12-10